ABSTRACT
T HE USE OF COMBINATIONS OF ANTIRETROVIRAL (ARV)
has shown remarkable outcomes in controlling human immunodeficiency virus type 1 (HIV-1) disease progression and extending the survival of these patients. [1] [2] [3] [4] As in many other developing countries, highly active antiretroviral therapy (HAART) has not been universally available to HIV-infected patients in Malaysia. Zidovudine first became available in Malaysia in 1991. In 1996 didanosine and later stavudine and lamivudine were added to the list of nucleoside reverse transcriptase inhibitors (NRTIs) that were available for treatment. The first protease inhibitor to become available for use in Malaysia was indinavir in 1997, which was followed by ritonavir. The nonnucleoside reverse transcriptase inhibitor (NNRTI) efavirenz became available in 1999 and subsequently nevirapine was available for use. In June 2002 a total of 13 ARV agents were available including five NRTIs, six protease inhibitors (PIs), and two NNRTIs. In a study of two large HIV clinics in Malaysia, didanosine was the most commonly used NRTIs followed by zidovudine and stavudine. In HAART combinations, drugs in the NNRTI class, efavirenz and nevirapine were more commonly used than PIs. The most common protease inhibitor prescribed was indinavir. In this study approximately 64% of all patients in 2002 were receiving HAART with a median CD4 lymphocyte count at starting HAART of 118 cells/mm 3 . 5 Although HAART has become increasingly affordable and accessible through importation of generic ARV agents, access remains limited with only 22% of those in need of ARV in Malaysia receiving therapy in a survey performed in 2004 (http://web.amfar.org/treatment/news/TADoc7.pdf).
The major obstacle in using HAART to sustain the suppression of HIV is the development of drug-resistance. [6] [7] [8] In developed countries, the prevalence of drug-resistant virus among recent seroconverters and treatment-naive patients has increased in recent years, ranging from 0 to 27% in major (or "primary") drug resistance mutations. [9] [10] [11] [12] [13] [14] There is also a significantly high percentage of minor (or "secondary") mutations detected in these patients. Genotypic testing among drug-naive patients is therefore important in clinical settings for detection of baseline mutations prior to initiating ARV therapy, particularly when access to ARV drugs has been upscaled and the level of transmitted resistance is high. In Malaysia, drug resistance testing among the ARV-naive population will provide a mechanism for monitoring treatment programs in the country.
One-hundred ARV-naive HIV-1-positive individuals attending the HIV Clinic at University Malaya Medical Center (UMMC) in Kuala Lumpur, Malaysia, were selected from June 2003 to July 2004. The study was approved by the Research and Ethics Committee of the UMMC. Information on the patients' ARV status was collected from the HIV clinic patient management database and verified through a chart review. The majority of the patients were male (81%), with a median age of 36 years (range 9-67 years) and were from the Chinese ethnic group (65%). The major route of HIV transmission was through heterosexual contact (57%). A total of 60%, 10%, and 13% of the plasma was collected within 2 months, 3-12 months, and more than 12 months after the first positive HIV-1 testing, respectively. No dates of first positive HIV test were available in 17% of the patients.
HIV-1 RNA was extracted by a column purification method (QIAamp Viral RNA Mini Kit, Qiagen, Hilden, Germany) and reverse transcribed to cDNA before nested PCR was performed as previously described. 15 Briefly, for RT gene amplification, primers RT-2955 (5Ј GCT TTA CCT TAA TCC CTG CAT AAT 3Ј) and A-35 (5Ј GGT TGT ACT TTA AAT TTC CCA ATT AGT CC 3Ј) were used in the first PCR followed by primers B887-2 (5Ј CTG TAC CAG TAA CAT TAA AGC CAG G 3Ј) and RT-2923 (5Ј GCC CAA TTT AGT TTT CCC ACT AAT 3Ј) in the second PCR. For protease gene, primers PI-1685 (5Ј GGA ATT TTC CTC AGA GCA GAC CAG 3Ј) and PI-2209 (5Ј TCT TCT GTC AAT GGC CAC TGT TTA AC 3Ј) were used in the first PCR and primers PI-1685 and PI-2172 (5Ј CCA TTC CTG GCT TTA ATG TTA CTG GTA C 3Ј) were applied in the second PCR. The nucleotide sequences of RT and protease genes were determined by the cycle-sequencing dideoxy chain termination method in an ABI PRISM 3100 automated DNA sequencer (Applied Biosystems, Foster City, CA). Electropherograms were analyzed and adjusted manually and DNA sequences were then translated to amino acids.
Codons 1-96 of the protease and 20-255 of the RT were manually inspected and scored for major and minor mutations previously reported to be associated with antiretroviral resistance by the International AIDS Society-USA (IAS-USA) Drug Resistance Mutations Group. 16 Based on the fact that certain mutations are of high frequency for selection by ARV treatments and/or their involvement in resistance to one or several ARV drugs, these mutations are termed major resistance mutations while the other mutations are considered minor resistance mutations. In our analysis, M41L, K65R, D67N, insertion 69, K70R, L74V, L100I, K103N, V106A/M, Q151M, Y181C/I, M184V/I, Y188C/L/H, G190A/S, L210W, T215Y/F, K219Q/E, and M230L in the RT gene and D30N, M46I/L, G48V, I50V, V82A/T/F/S, I84V, and L90M in the protease gene were considered as major resistance mutations. In addition, several minor mutations (or polymorphisms) not reported by the IAS-USA Drug Resistance Mutations Group were also analyzed in the study. To study the difference of proportions of TEE ET AL. 122 ARV-associated mutations between different subtypes, major and minor mutations were compared using two-tailed Fischer's exact test and p Ͻ 0.05 was considered to be significant. From 100 patients, 88% were harboring the non-B subtype and only 12% were subtype B, as previously determined by phylogenetic analysis on RT and protease genes. 15 CRF01_AE and CRF01_AE/B intersubtype recombinants were detected at 64% and 22%, respectively. Subtype C and an undetermined subtype (subtype G or H) were present at 1% each. Among 19 CRF01_AE/B recombinants, similar recombination breakpoints were estimated at codon L33 and K103 in the protease and RT genes, respectively; in both genes the 5Ј subregion prior to the breakpoint was subtype B and the 3Ј subregion was CRF01_AE.
The frequency of major ARV-associated amino acid substitution was examined within the RT and protease coding region (Table 1) . Only one patient (1%) was found to have at least one major mutation conferring resistance to NRTIs, NNRTIs, or PIs. Patient 03MYKL1425, who was infected with CRF01_AE, had the Y181C major mutation in the RT gene that confers highlevel resistance to nevirapine (NVP) and delavirdine (DLV). No major mutations were detected in both RT and protease genes among other patients.
Mutations were compared between CRF01_AE and subtype B by two-tailed Fischer's exact test to examine the difference in the proportion of antiretroviral-associated mutations. CRF01_AE/B recombinants were excluded in the statistical analysis since the nucleotide sequences contain both the subtype B and CRF01_AE fragments. No significant difference was observed in both major and minor drug resistance mutations between CRF01_AE and subtype B in the RT gene. However, in contrast to the low prevalence of major mutations, minor mutations (or polymorphisms) were frequently detected in the protease gene (Table 1) . Amino acid substitutions I13V (p Ͻ 0.0001), E35D (p ϭ 0.004), and M36I (p Ͻ 0.0001) were significantly associated with CRF01_AE while L63P (p Ͻ 0.0001), V77I (p ϭ 0.026), and I93L (p ϭ 0.001) were linked with subtype B. Multiple comparisons were adjusted between minor protease mutations, with the result showing that the presence of mutations I13V (p ϭ 0.008), E35D (p ϭ 0.0001), M36I (p Ͻ 0.0001), and L63P (p ϭ 0.001) was not affected by other mutations and could significantly predict the subtype. This is the first study in which major and minor mutations associated with ARV resistance were surveyed among ARVnaive HIV-1 patients in an urban population in Kuala Lumpur during the HAART era. The majority of the patients in this study were recently diagnosed. The prevalence of major mutations associated with high-level resistance to at least one ARV drug was low. However, the low prevalence could be influenced by the reversion of the resistant quasispecies to the wild type among patients who were sampled a few months or later after the first positive HIV-1 testing. 17 Patient 03MYKL1425, who contracted HIV-1 through heterosexual activity, was diagnosed with HIV-1 infection on October 2002 and was not on any form of ARV treatment until September 2003 when the plasma sample was collected. No information was available from this patient's sexual partner. The presence of the Tyr181Cys mutation, probably due to the increased use of NNRTIs in ARV therapy, 5 showed that the transmitted drugresistant variants can persist for at least a year in the absence of selective drug pressure. [18] [19] [20] Nevertheless other studies have demonstrated that the acquired Y181C variant often reverts to the wild type after several weeks. 21 In contrast to major mutations, minor mutations were frequently present in the protease gene, reducing the "genetic barrier" to drug resistance by increasing the selection of resistant strains. Understanding of the roles of these polymorphic codons, alone or in combination, is limited. Recent studies have shown that the clinical response to ARV therapy is independent of HIV-1 subtype and baseline polymorphisms of the protease gene. 22, 23 However, other studies have suggested that the presence of minor protease mutations is associated with the development of resistance to protease inhibitors and subsequently reduced efficacy to PI-based therapy. 24, 25 Thus, long-term assessment of patients receiving ARV therapy is needed to establish the clinical impact of protease polymorphisms, particularly among patients with CRF01_AE, which is also the major circulating strain in the Southeast Asia region.
The low prevalence estimated in this study, mainly represents the newly diagnosed urban populations in Kuala Lumpur that have not been previously exposed to ARV, suggesting that routine drug resistance testing may be unnecessary for all individuals newly diagnosed or patients beginning ARV therapy. As one of the essential components of the new WHO HIV Drug Resistance Surveillance and Monitoring strategy, 26 monitoring of the emergence of drug-resistant HIV in populations starting first-line ARV therapy would be a useful approach for planning effective treatment programs in the country. A minimumresource approach called the HIV Drug Resistance Threshold Survey recommended by WHO, meanwhile, would best reflect the transmission of drug-resistant HIV in a recently infected population.
Nucleotide sequences of 100 protease and RT genes were submitted to GenBank under accession numbers AY904519-AY904618 and AY904619-AY904718, respectively.
